A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis (NCT06096779)

🧪 Interventions in This Study

• Atezolizumab (DRUG)
• Bevacizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (59 Sites)

Showing the first 25 of 59 sites.

• University of Arizona Cancer Center — Tucson, Arizona
• UC San Diego Moores Cancer Center — La Jolla, California
• University of Southern California-Keck School of Medicine -1975 Zonal Ave — Los Angeles, California
• University of Southern California — Newport Beach, California
• University of California Irvine Medical Center — Orange, California
• California Liver Research Institute — Pasadena, California
• University of California Davis Medical Center — Sacramento, California
• Stanford Health Care — Stanford, California
• Harbor UCLA Medical Center — Torrance, California
• Cedars Sinai Comprehensive Transplant Center — West Hollywood, California
• Rocky Mountain Cancer Centers (Williams) - USOR — Denver, Colorado
• Hartford Healthcare Cancer Institute at Hartford Hospital — Hartford, Connecticut
• George Washington University- Medical Faculty Associates — Washington D.C., District of Columbia
• Washington DC VA Medical Center — Washington D.C., District of Columbia
• Orlando Health Inc. — Orlando, Florida
• Northwestern University — Chicago, Illinois
• University of Illinois Health Outpatient Care Center — Chicago, Illinois
• The Duchossois Center for Advanced Medicine — Chicago, Illinois
• University of Kentucky - Markey Cancer Center — Lexington, Kentucky
• LSU Health Baton Rouge — Baton Rouge, Louisiana
• Our Lady of the Lake Cancer Institute — Baton Rouge, Louisiana
• Tufts Medical Center — Boston, Massachusetts
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Veterans Affairs Ann Arbor Healthcare System — Ann Arbor, Michigan
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hepatocellular Carcinoma

• TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients — Maywood, Illinois
• Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab — San Diego, California
• Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) — Baltimore, Maryland
• TheraSphere With Durvalumab and Tremelimumab for HCC — San Diego, California
• Blood Salvage in Orthotopic Liver Transplantation With HCC — Toronto, Ontario
• Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) — Prescott Valley, Arizona

Explore by condition: All Hepatocellular Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.